<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7026129</article-id><article-id pub-id-type="doi">10.3389/fmicb.2020.00150</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Takayama-Ito</surname><given-names>Mutsuyo</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/818591/overview"/></contrib><contrib contrib-type="author"><name><surname>Saijo</surname><given-names>Masayuki</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/43345/overview"/></contrib></contrib-group><aff><institution>Department of Virology I, National Institute of Infectious Diseases</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lijun Rong, The University of Illinois at Chicago, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Takashi Irie, Hiroshima University, Japan; Alexander Freiberg, The University of Texas Medical Branch at Galveston, United States</p></fn><corresp id="c001">*Correspondence: Masayuki Saijo <email>msaijo@nih.go.jp</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Virology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>11</volume><elocation-id>150</elocation-id><history><date date-type="received"><day>30</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Takayama-Ito and Saijo.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Takayama-Ito and Saijo</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by SFTS virus (SFTSV), which is a novel bunyavirus. SFTSV was first isolated from patients who presented with fever, thrombocytopenia, leukocytopenia, and multiorgan dysfunction in China. Subsequently, it was found to be widely distributed in Southeast Asia (Korea, Japan, and Vietnam). SFTSV can be transmitted not only from ticks but also from domestic animals, companion animals, and humans. Because the case fatality rate of SFTS is high (6&#x02013;30%), development of specific and effective treatment for SFTS is required. Studies of potential antiviral drugs for SFTS-specific therapy have been conducted on existing or newly discovered agents <italic>in vitro</italic> and <italic>in vivo</italic>, with ribavirin and favipiravir being the most promising candidates. While animal experiments and retrospective studies have demonstrated the limited efficacy of ribavirin, it was also speculated that ribavirin would be effective in patients with a viral load &#x0003c;1 &#x000d7; 10<sup>6</sup> copies/mL. Favipiravir showed higher efficacy than ribavirin against SFTSV in <italic>in vitro</italic> assays and greater efficacy in animal models, even administrated 3 days after the virus inoculation. Although clinical trials evaluating the efficacy of favipiravir in SFTS patients in Japan are underway, this has yet to be confirmed. Other drugs, including hexachlorophene, calcium channel blockers, 2&#x02032;-fluoro-2&#x02032;-deoxycytidine, caffeic acid, amodiaquine, and interferons, have also been evaluated for their inhibitory efficacy against SFTSV. Among them, calcium channel blockers are promising because in addition to their efficacy <italic>in vitro</italic> and <italic>in vivo</italic>, retrospective clinical data have indicated that nifedipine, one of the calcium channel blockers, reduced the case fatality rate by &#x0003e;5-fold. Although further research is necessary to develop SFTS-specific therapy, considerable progress has been achieved in this area. Here we summarize and discuss recent advances in antiviral drugs against SFTSV.</p></abstract><kwd-group><kwd>severe fever with thrombocytopenia syndrome</kwd><kwd>severe fever with thrombocytopenia syndrome virus</kwd><kwd>antiviral</kwd><kwd>ribavirin</kwd><kwd>favipiravir</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Ministry of Health, Labour and Welfare<named-content content-type="fundref-id">10.13039/501100003478</named-content></funding-source><award-id rid="cn001">H25-Shinko-Shitei-009</award-id></award-group><award-group><funding-source id="cn002">Japan Agency for Medical Research and Development<named-content content-type="fundref-id">10.13039/100009619</named-content></funding-source><award-id rid="cn002">16fk0108002j</award-id><award-id rid="cn002">17fk0108202j</award-id><award-id rid="cn002">18fk0108002j</award-id><award-id rid="cn002">19fk0108072j</award-id><award-id rid="cn002">19fk0108081j</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="79"/><page-count count="10"/><word-count count="8184"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by SFTS virus (SFTSV), a novel bunyavirus classified into the genus <italic>Phlebovirus</italic> and family <italic>Bunyaviridae</italic> according to the previous nomenclature by the International Committee of Taxonomy of Viruses (ICTV). However, according to the nomenclature by the ICTV, SFTSV has been classified into the Genus <italic>Banyangvirus</italic>, Family <italic>Phenuiviridae</italic> and re-named as <italic>Huaiyangshan banyangvirus</italic>. In this review article, we have referred to it as &#x0201c;SFTSV.&#x0201d; SFTSV is a negative-stranded RNA virus and its genome comprises of three segments, designated as large (L), medium (M), and small (S). The L and M segments encode the RNA dependent RNA polymerase (RdRp) and glycoprotein precursors (Gn and Gc), respectively, and S segment encodes nucleoprotein and nonstructural proteins. The RdRp of SFTSV is responsible for viral replication and is a major target of nucleoside analogs, which are used as therapeutic antiviral drugs. The Gn and Gc are presented on the surface of the virion and are the main targets of neutralizing antibodies. SFTSV was first isolated from patients who presented with fever, thrombocytopenia, leukocytopenia, and multiorgan dysfunction in Hubei and Henan provinces in Central China (Yu et al., <xref rid="B76" ref-type="bibr">2011</xref>). Subsequently, the virus was isolated from sick patients in Japan and South Korea, indicating that SFTSV was endemic not only to China, but also to South Korea and Japan (Kim et al., <xref rid="B30" ref-type="bibr">2013</xref>; Takahashi et al., <xref rid="B61" ref-type="bibr">2014</xref>). In addition, recent studies have reported SFTS as endemic to Vietnam (Tran et al., <xref rid="B66" ref-type="bibr">2019</xref>) and Xinjiang, China (Zhu et al., <xref rid="B78" ref-type="bibr">2019</xref>), indicating that the distribution of SFTSV in Southeast Asia might be much more extensive than expected. Humans become infected mainly via tick-bites, but through close contact with animals such as cats, and dogs and human-to-human transmission has also been reported (Gai et al., <xref rid="B18" ref-type="bibr">2012</xref>; Niu et al., <xref rid="B47" ref-type="bibr">2013</xref>; Kida et al., <xref rid="B28" ref-type="bibr">2019</xref>). The case fatality rate of SFTS is found to vary between 6 and 30% in Japan and South Korea, with a fatality rate of approximately 30% (Choi et al., <xref rid="B8" ref-type="bibr">2016</xref>; Kato et al., <xref rid="B27" ref-type="bibr">2016</xref>). Although World Health Organization listed SFTS as a disease requiring urgent research and development (World Health Organization, <xref rid="B73" ref-type="bibr">2017</xref>), there is no available effective SFTS treatment.</p><p>The development of vaccines against SFTSV infection has been attempted (Dong et al., <xref rid="B15" ref-type="bibr">2019</xref>; Kwak et al., <xref rid="B33" ref-type="bibr">2019</xref>). The development of specific treatment for SFTS is crucial because SFTSV infection is relatively rare and the affected patients are mainly elderly. Some proposed treatments for SFTS include steroid pulse therapy (Nakamura et al., <xref rid="B45" ref-type="bibr">2018</xref>), plasma exchange (Oh et al., <xref rid="B49" ref-type="bibr">2014</xref>; Yoo et al., <xref rid="B74" ref-type="bibr">2019</xref>), and antiviral drugs (Saijo, <xref rid="B51" ref-type="bibr">2018</xref>); however, their effectiveness remains unclear.</p><p>SFTSV infects a variety of cultured cells, including L929, Vero E6, Vero, and DH82 cells (Yu et al., <xref rid="B76" ref-type="bibr">2011</xref>). Several studies have been conducted to identify effective antiviral agents against SFTSV by screening compound libraries or testing agents that are effective against other viruses (<xref rid="T1" ref-type="table">Table 1</xref>). Because it has been suggested that antiviral drugs may potentially be effective in treatment of multiple viral infections, testing approved drugs is considered as a reasonable strategy (De Clercq and Li, <xref rid="B11" ref-type="bibr">2016</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Efficacy of anti-SFTSV drugs <italic>in vitro</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Agent</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Cells</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Study design</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Strain of SFTSV</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>IC<sub><bold>50/90/99</bold></sub></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>CC<sub><bold>50</bold></sub></bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 263 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;1,929 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Shimojima et al., <xref rid="B57" ref-type="bibr">2014</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Huh7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 83 &#x003bc;M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">U2OS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 78 &#x003bc;M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL030)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 424 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;1,929 &#x003bc;M</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Huh7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 63 &#x003bc;M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">U2OS</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>99</sub> = 73 &#x003bc;M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL030)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>90</sub> = 176 &#x003bc;M<xref ref-type="table-fn" rid="TN1"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;2,000 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Shimojima et al., <xref rid="B56" ref-type="bibr">2015</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Korean isolate strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 15.1&#x02013;35.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;128 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Lee et al., <xref rid="B36" ref-type="bibr">2017</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Japanese isolate strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 40.1 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;100 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Baba et al., <xref rid="B1" ref-type="bibr">2017</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 49.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;320 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Smee et al., <xref rid="B58" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL010)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 6 &#x003bc;M, IC<sub>90</sub> = 22 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;1,000 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Tani et al., <xref rid="B63" ref-type="bibr">2016</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Japanese isolate strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 25 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;100 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Baba et al., <xref rid="B1" ref-type="bibr">2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hexachlorophene</td><td valign="top" align="left" rowspan="1" colspan="1">Vero, Huh7</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 1.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">24.3 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Yuan et al., <xref rid="B77" ref-type="bibr">2019</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sup>99</sup> = 7.5 &#x003bc;M</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Benidipine</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 1.412 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">96.92 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Li et al., <xref rid="B38" ref-type="bibr">2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nifedipine</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 98 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;250 &#x003bc;M</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02032;-Fluoro- 2&#x02032;-deoxycytidine</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>90</sub> = 3.7 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;320 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Smee et al., <xref rid="B58" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Caffeic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Huh7.5.1&#x02013;8</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 48 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">7.6 mM</td><td valign="top" align="left" rowspan="1" colspan="1">Ogawa et al., <xref rid="B48" ref-type="bibr">2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amodiaquine</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction<xref ref-type="table-fn" rid="TN2"><sup>**</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Japanese isolates strain</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>50</sub> = 19.1 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;100 &#x003bc;M</td><td valign="top" align="left" rowspan="1" colspan="1">Baba et al., <xref rid="B1" ref-type="bibr">2017</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN&#x003b1;</td><td valign="top" align="left" rowspan="1" colspan="1">Vero</td><td valign="top" align="left" rowspan="1" colspan="1">Yield reduction</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL030)</td><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>90</sub> = 29 U/ml</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;5,000 U/mL</td><td valign="top" align="left" rowspan="1" colspan="1">Shimojima et al., <xref rid="B56" ref-type="bibr">2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN&#x003b2;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>90</sub> = 24 U/ml</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;5,000 U/mL</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN&#x003b3;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IC<sub>90</sub> = 12 ng/ml</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;2,000 ng/mL</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p><italic>Combination with ribavirin and IFNs, virus titers were reduced from 3.2&#x02013;3.6 log</italic>.</p></fn><fn id="TN2"><label>**</label><p><italic>Titers were determined by RT-PCR of the virus genome</italic>.</p></fn></table-wrap-foot></table-wrap><p>Sufficient animal models are required to evaluate the efficacy of antiviral drugs in the treatment of SFTSV infections. However, adult mice and hamsters are not susceptible to SFTSV infection (Jin et al., <xref rid="B26" ref-type="bibr">2012</xref>) and non-human primate models show only mild symptoms similar to those of SFTS in humans (Jin et al., <xref rid="B25" ref-type="bibr">2015</xref>). Only several immunodeficient or immature animal models are available (Gowen and Hickerson, <xref rid="B21" ref-type="bibr">2017</xref>). Mice deficient in &#x003b1;/&#x003b2; interferon receptor (IFNAR<sup>&#x02212;/&#x02212;</sup>) (Liu et al., <xref rid="B40" ref-type="bibr">2014</xref>; Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>) and mice and Syrian hamsters deficient for the gene encoding signal transducer and the activator of transcription 2 (STAT2<sup>&#x02212;/&#x02212;</sup>) (Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>; Yoshikawa et al., <xref rid="B75" ref-type="bibr">2019</xref>) were found to be susceptible to SFTSV infection following subcutaneous inoculation, and newborn mice and rats were susceptible to SFTSV infection when inoculated intracerebrally (Chen et al., <xref rid="B7" ref-type="bibr">2012</xref>; Zivcec et al., <xref rid="B79" ref-type="bibr">2013</xref>; Ning et al., <xref rid="B46" ref-type="bibr">2019</xref>). <xref rid="T2" ref-type="table">Table 2</xref> presents animal models that have been used to determine the efficacy of antiviral drugs against SFTSV infections.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Efficacy of anti-SFTSV drugs <italic>in vivo</italic> animal model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Agent</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Animals</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Dose of agent (times/day)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Route</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Treatment</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Strain</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Dose of virus</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Route</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Survival (%)</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ribavirin</td><td valign="top" align="left" rowspan="1" colspan="1">STAT2<sup>&#x02212;/&#x02212;</sup>hamster</td><td valign="top" align="left" rowspan="1" colspan="1">75 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 1&#x02013;11</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">50 PFU</td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">IFNAR<sup>&#x02212;/&#x02212;</sup>C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">25 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;5</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL010)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">70</td><td valign="top" align="left" rowspan="1" colspan="1">Tani et al., <xref rid="B63" ref-type="bibr">2016</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">100 mg/kg/day (once)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Favipiravir</td><td valign="top" align="left" rowspan="1" colspan="1">IFNAR<sup>&#x02212;/&#x02212;</sup>C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">60 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;5</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL010)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">Tani et al., <xref rid="B63" ref-type="bibr">2016</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">300 mg/kg/day (once)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">60 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">300 mg/kg/day (once)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">300 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 1&#x02013;6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 2&#x02013;7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 3&#x02013;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 4&#x02013;9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 5&#x02013;10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">120 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;4</td><td valign="top" align="left" rowspan="1" colspan="1">Japanese strain (SPL010)</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>6</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">Tani et al., <xref rid="B64" ref-type="bibr">2018</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 1&#x02013;5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 2&#x02013;6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 3&#x02013;7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 4&#x02013;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 5&#x02013;9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">200 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 1&#x02013;5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 2&#x02013;6</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 3&#x02013;7</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 4&#x02013;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 5&#x02013;9</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">100 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;8</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">3 PFU</td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">90</td><td valign="top" align="left" rowspan="1" colspan="1">Smee et al., <xref rid="B58" ref-type="bibr">2018</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">STAT2<sup>&#x02212;/&#x02212;</sup>hamster</td><td valign="top" align="left" rowspan="1" colspan="1">300 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">p.o.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 1&#x02013;11</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">50 PFU</td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">150 mg/kg/day (twice)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Benidipine</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">15 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">i.g.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;7</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="center" rowspan="1" colspan="1">100<xref ref-type="table-fn" rid="TN3"><sup>*</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">Li et al., <xref rid="B38" ref-type="bibr">2019</xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Humanized mouse</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">83.3<xref ref-type="table-fn" rid="TN4"><sup>**</sup></xref></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nifedipine</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">100 mg/kg/day (once)</td><td valign="top" align="left" rowspan="1" colspan="1">i.g.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;7</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="center" rowspan="1" colspan="1">100<xref ref-type="table-fn" rid="TN3"><sup>*</sup></xref></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Humanized mice</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100<xref ref-type="table-fn" rid="TN4"><sup>**</sup></xref></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2&#x02032;-FdC<xref ref-type="table-fn" rid="TN5"><sup>***</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">IFNAR<sup>&#x02212;/&#x02212;</sup>C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">50 mg/kg/day (twice)</td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;8</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese strain (HB29)</td><td valign="top" align="left" rowspan="1" colspan="1">3 PFU</td><td valign="top" align="left" rowspan="1" colspan="1">s.c.</td><td valign="top" align="center" rowspan="1" colspan="1">80</td><td valign="top" align="left" rowspan="1" colspan="1">Smee et al., <xref rid="B58" ref-type="bibr">2018</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">100 mg/kg/day (twice)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">200 mg/kg/day (twice)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day 0&#x02013;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b3;</td><td valign="top" align="left" rowspan="1" colspan="1">3 days old ICR</td><td valign="top" align="left" rowspan="1" colspan="1">0.5 &#x003bc;g/animal (once)</td><td valign="top" align="left" rowspan="1" colspan="1">i.p.</td><td valign="top" align="left" rowspan="1" colspan="1">Day &#x02212;1</td><td valign="top" align="left" rowspan="1" colspan="1">unknown</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 &#x000d7; 10<sup>3</sup> TCID<sub>50</sub></td><td valign="top" align="left" rowspan="1" colspan="1">i.c.</td><td valign="top" align="center" rowspan="1" colspan="1">25</td><td valign="top" align="left" rowspan="1" colspan="1">Ning et al., <xref rid="B46" ref-type="bibr">2019</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.05 &#x003bc;g/animal (once)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.5 &#x003bc;g/animal (once)</td><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Day +1</td><td valign="top" align="left" rowspan="1" colspan="1">unknown</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 &#x000d7; 10<sup>3</sup> TCID<sub>50</sub></td><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.05 &#x003bc;g/animal (once)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="TN3"><label>*</label><p><italic>Non-lethal model. The viral loads in spleen and serum were significantly reduced</italic>.</p></fn><fn id="TN4"><label>**</label><p><italic>The fatality rate of the vehicle control group was 57.1%</italic>.</p></fn><fn id="TN5"><label>***</label><p><italic>2&#x02032;-Fluoro-2&#x02032;-deoxycytidine</italic>.</p></fn><p><italic>i.g., inguinal; i.p., intraperitoneal; PFU, plaque-forming unit; p.o., oral; s.c., subcutaneous; TCID, tissue culture infective dose</italic>.</p></table-wrap-foot></table-wrap><p>In this review article, we summarize and discuss recent advancements made in SFTSV treatment using antiviral drugs.</p></sec><sec id="s2"><title>Potential Therapeutic Drugs Against SFTS</title><sec><title>Ribavirin</title><p>Ribavirin, a nucleotide analog, exerts a broad spectrum of antiviral activity against various viruses, such as respiratory syncytial virus, influenza, measles, herpesvirus, human immunodeficiency virus, Lassa virus, and [in combination with interferon (IFN)-&#x003b1;] hepatitis C virus. Ribavirin can be administered orally, intravenously, or via a nebulizer (Snell, <xref rid="B59" ref-type="bibr">2001</xref>). The proposed mechanisms of action of ribavirin against viruses are indirect (inosine monophosphate dehydrogenase inhibition and immunomodulatory effects) as well as direct (interference with RNA capping, polymerase inhibition, and lethal mutagenesis) (Graci and Cameron, <xref rid="B23" ref-type="bibr">2006</xref>).</p><p>Shimojima et al. (<xref rid="B57" ref-type="bibr">2014</xref>) first reported the efficacy of ribavirin <italic>in vitro</italic> using three cell lines: monkey kidney-derived Vero, human hepatoma-derived Huh7, and human osteosarcoma-derived U2OS cells. When treated with ribavirin before and during infection with SFTSV, the 99% inhibitory concentration (IC<sub>99</sub>) of ribavirin was 263, 83, and 78 &#x003bc;M in Vero, Huh7, and U2OS cells, respectively (<xref rid="T1" ref-type="table">Table 1</xref>). However, when Vero cells were treated with ribavirin 3 days after the inoculation, the inhibitory effect was dramatically decreased, suggesting that ribavirin could be used as post-exposure prophylaxis for the prevention of SFTS and also mentioned that ribavirin could be effective as part of a combination therapy to treat SFTS patients (Shimojima et al., <xref rid="B57" ref-type="bibr">2014</xref>). The efficacy of ribavirin against SFTSV replication was also observed in another study, where Vero cells infected with a Korean SFTSV strain were treated at 24 and 48 h post inoculation, and the 50% inhibitory concentration (IC<sub>50</sub>) range was 3.69&#x02013;8.72 &#x003bc;g/mL (Lee et al., <xref rid="B36" ref-type="bibr">2017</xref>) (<xref rid="T1" ref-type="table">Table 1</xref>). Despite several differences in viral strains and treatment procedure, ribavirin suppressed SFTS replication, suggesting that it was effective against various SFTSVs for at least 48 h after SFTSV inoculation.</p><p>Shimojima et al. (<xref rid="B56" ref-type="bibr">2015</xref>) investigated the improvement in efficacy when ribavirin was used in combination with IFNs. All IFNs showed dose-dependent inhibitory effects when used alone. The IC<sub>90</sub> of IFN&#x003b1;, IFN&#x003b2;, and IFN&#x003b3; was 29 U/ml, 24 U/ml, and 12 ng/ml, respectively, and that of ribavirin was 43 &#x003bc;g/mL (<xref rid="T1" ref-type="table">Table 1</xref>). When IFNs were combined with ribavirin at IC<sub>90</sub>, significant inhibitory effects were observed, with reductions of &#x0003e;3 log<sub>10</sub> in viral titers. This study suggested that the combination of ribavirin with IFNs or other agents that function via different mechanisms might be useful in treating patients with SFTS. Ribavirin has shown a limited protective effect in lethal SFTSV challenges in animal experiments (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>; Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>) (<xref rid="T2" ref-type="table">Table 2</xref>). The Chinese Ministry of Health initially approved the use of ribavirin to treat SFTS based on the results of <italic>in vitro</italic> studies (Ministry of Health People's Republic of China, <xref rid="B43" ref-type="bibr">2011</xref>). However, a clinical study in China showed that the case fatality rate was similar between patients who received ribavirin and those who did not (Liu et al., <xref rid="B39" ref-type="bibr">2013</xref>). This study included 311 patients, of whom 54 died; in those who received ribavirin therapy, the platelet counts did not increase and the viral loads did not decrease in comparison with those who did not receive the therapy. Furthermore, although the differences were not statistically significant, it was unexpectedly observed that the patients who received ribavirin therapy had lower platelet counts than those who did not.</p><p>Another study reported that two patients, in whom plasma exchange and ribavirin treatment were initiated early, recovered from rapidly progressing SFTS (Oh et al., <xref rid="B49" ref-type="bibr">2014</xref>). In these patients, the platelet counts began to gradually recover after initiating ribavirin treatment. Furthermore, according to a large-scale epidemiological study in China including 2096 patients with laboratory-confirmed SFTS between 2011 and 2017, ribavirin therapy was effective in reducing the case fatality rate from 6.25% (15/240 patients) to 1.16% (2/173 patients) in patients with viral loads of &#x0003c;1 &#x000d7; 10<sup>6</sup> copies/mL (Li et al., <xref rid="B37" ref-type="bibr">2018</xref>). However, no effect was observed among those with a viral load of &#x0003e;1 &#x000d7; 10<sup>6</sup> copies/mL.</p></sec><sec><title>Favipiravir</title><p>Favipiravir (T-705), which was discovered and synthesized by Toyama Chemical Co., Ltd., exerts a broad spectrum of activity against various RNA viruses, including the influenza virus, arenaviruses, bunyaviruses, West Nile virus, yellow fever virus, and foot-and-mouth disease virus (Furuta et al., <xref rid="B17" ref-type="bibr">2009</xref>). Favipiravir is converted to its active form, ribofuranosyl-5-triphosphate, by host enzymes and inhibits viral RNA polymerase in the host cells. Only a few reports have indicated resistance to favipiravir <italic>in vitro</italic> (Delang et al., <xref rid="B12" ref-type="bibr">2014</xref>; Goldhill et al., <xref rid="B20" ref-type="bibr">2018</xref>). As shown in <xref rid="T1" ref-type="table">Tables 1</xref>, <xref rid="T2" ref-type="table">2</xref> favipiravir significantly inhibits SFTSV replication <italic>in vitro</italic> (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>; Baba et al., <xref rid="B1" ref-type="bibr">2017</xref>) and <italic>in vivo</italic> (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>, <xref rid="B64" ref-type="bibr">2018</xref>; Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>; Smee et al., <xref rid="B58" ref-type="bibr">2018</xref>). Furthermore, the IC<sub>90</sub> of favipiravir (22 &#x003bc;M) in Vero cells (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>) was lower than that of ribavirin (263 &#x003bc;M) (Shimojima et al., <xref rid="B57" ref-type="bibr">2014</xref>).</p><p>The efficacy of favipiravir <italic>in vivo</italic> has been examined using animal models (<xref rid="T2" ref-type="table">Table 2</xref>). The intraperitoneal (i.p.) administration of favipiravir at a dose of 60 or 300 mg/kg/day for 5 days completely protected mice from death upon SFTSV infection, causing only a slight reduction in weight (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>). On the other hand, ~40% of the mice treated with ribavirin (i.p.) at a dose of 25 or 100 mg/kg/day lost body weight and died from SFTSV infection with reduction of the case fatality rate. All favipiravir-treated mice survived when the treatment was initiated on or earlier than 3 days post infection, whereas the mice treated at 4 and 5 days post infection exhibited 83% and 50% survival, respectively (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>). These results demonstrated that favipiravir would be potentially effective for prophylactic use and also for treating of SFTSV infections.</p><p>Generally, favipiravir is orally administrated to humans. The oral administration (p.o.) of favipiravir showed similar efficacy to that of i.p. administration in a mouse model (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>). Furthermore, treatment with favipiravir (300 or 150 mg/kg/day) provided complete protection against a lethal SFTSV challenge in a STAT2 knockout golden Syrian hamster model (Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>). Additionally, the efficacy of favipiravir at practical dosages of 120 and 200 mg/kg/day p.o. was investigated in a mouse infection model, and all the mice survived when the treatment was initiated at no later than 4 days post infection (Tani et al., <xref rid="B64" ref-type="bibr">2018</xref>).</p></sec><sec><title>Hexachlorophene</title><p>Yuan et al. (<xref rid="B77" ref-type="bibr">2019</xref>) screened an FDA-approved drug library that contained 1,528 drug compounds and identified five that inhibited SFTSV replication at concentrations of &#x0003c;10 &#x003bc;M, including two antibacterial and antifungal disinfectants (hexachlorophene and triclosan), a multi-kinase inhibitor for the treatment of advanced solid organ tumors (regorafenib), a small molecule agonist of the C-mannosylation of thrombopoietin receptor (c-Mpl) for the treatment of immune thrombocytopenic purpura and aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline). Of them, hexachlorophene was the most potent, with an IC<sub>50</sub> of 1.3 &#x000b1; 0.3 &#x003bc;M (RNA load) and 2.6 &#x000b1; 0.14 &#x003bc;M (plaque reduction) and the highest selectivity index (50% cytotoxic concentration [CC<sub>50</sub>]/IC<sub>50</sub>, 18.7), which was lower than that of the other four antiviral drugs identified (<xref rid="T1" ref-type="table">Table 1</xref>). Furthermore, the results indicated that hexachlorophene treatment interfered with SFTSV entry without affecting virus-host cell attachment to the cells and virus infectivity (Yuan et al., <xref rid="B77" ref-type="bibr">2019</xref>). It was predicted that hexachlorophene would bind to the deep hydrophobic pocket between domains I and III of the SFTSV Gc glycoprotein and would interfere with cell membrane fusion.</p><p>Hexachlorophene is an antibacterial compound, a common constituent of soaps and scrubs and is experimentally used as a cholinesterase inhibitor (Hsu et al., <xref rid="B24" ref-type="bibr">2004</xref>). It was reported that hexachlorophene inhibited the viral replication of severe acute respiratory syndrome-related coronavirus <italic>in vitro</italic> by inhibiting 3C-like protease, which is essential for its lifecycle (Hsu et al., <xref rid="B24" ref-type="bibr">2004</xref>).</p></sec><sec><title>Calcium Channel Blockers</title><p>Calcium channel blockers (CCBs) reduce the intracellular Ca<sup>2+</sup> level and are widely used for treating various cardiovascular diseases, including hypertension, angina, and supraventricular arrhythmias. Recently, the antiviral activity of CCBs against ebolavirus (Sakurai et al., <xref rid="B52" ref-type="bibr">2015</xref>), marburgvirus (Dewald et al., <xref rid="B13" ref-type="bibr">2018</xref>), Jun&#x000ed;n virus (Lavanya et al., <xref rid="B35" ref-type="bibr">2013</xref>), West Nile virus (Scherbik and Brinton, <xref rid="B54" ref-type="bibr">2010</xref>), and Japanese encephalitis virus (Wang et al., <xref rid="B69" ref-type="bibr">2017</xref>) has been reported.</p><p>Screening a library of 700 FDA-approved drugs identified the CCBs benidipine hydrochloride and nifedipine as inhibitors of SFTSV replication <italic>in vitro</italic> by impairing virus internalization and reducing genome replication during the post-entry phase (Li et al., <xref rid="B38" ref-type="bibr">2019</xref>). This mechanism did not affect viral binding, fusion, and budding. The results of <italic>in vitro</italic> study suggested that treatment with benidipine hydrochloride or nifedipine inhibited SFTSV replication by reducing virus induced Ca<sup>2+</sup> influx. The anti-SFTSV effect of these two CCBs was further analyzed in C57BL/6 mice and humanized mouse models (<xref rid="T2" ref-type="table">Table 2</xref>), revealing treatment effects of a reduced viral load, increased platelet count, and decreased fatality rate in the humanized mouse model.</p><p>Notably, nifedipine is one of the most widely used drugs for treating hypertension and atherosclerosis in China. Thus, Li et al. (<xref rid="B38" ref-type="bibr">2019</xref>) performed a retrospective clinical investigation on a large cohort of 2087 patients with SFTS comprising 83 nifedipine-treated, who received nifedipine before admission and during hospitalization, 48 non-nifedipine-treated ones who received nifedipine before admission but not during hospitalization, and 249 general SFTS patients who did not receive nifedipine at all. The case fatality rate was decreased by &#x0003e;5-fold in the nifedipine-treated group (3.6%) compared with the general SFTS group (19.7%) or non-nifedipine treated group (20.8%) (Li et al., <xref rid="B38" ref-type="bibr">2019</xref>). In contrast with ribavirin, a significant decrease in the case fatality rate was also observed in the nifedipine-treated patients (2.4%) with a high viral load (&#x0003e;10<sup>6</sup> copies/mL) when compared with the general SFTS patients (29.0%) and non-nifedipine-treated patients (34.5%). Hematemesis, one of the hemorrhagic manifestations that are closely related to death, was found to occur less frequently in the nifedipine-treated group. In this article, the authors clearly showed the inhibitory effect of benidipine hydrochloride or nifedipine in cultured cells and an animal model. Most importantly, it was found that the nifedipine administration enhanced virus clearance and improved clinical recovery.</p></sec><sec><title>2&#x02032;-Fluoro-2&#x02032;-deoxycytidine</title><p>2&#x02032;-Fluoro-2&#x02032;-deoxycytidine (2&#x02032;-FdC) is a nucleoside inhibitor used in anticancer drugs. It inhibits various RNA and DNA viruses <italic>in vitro</italic>, such as Borna virus (Bajramovic et al., <xref rid="B2" ref-type="bibr">2004</xref>), Lassa virus (Welch et al., <xref rid="B70" ref-type="bibr">2016</xref>), Crimean-Congo hemorrhagic fever virus (Welch et al., <xref rid="B71" ref-type="bibr">2017</xref>), influenza virus (Kumaki et al., <xref rid="B32" ref-type="bibr">2011</xref>), and herpesviruses (Wohlrab et al., <xref rid="B72" ref-type="bibr">1985</xref>).</p><p>Smee et al. (<xref rid="B58" ref-type="bibr">2018</xref>) has shown the antiviral activity of 2&#x02032;-FdC against various bunyaviruses, such as La Crosse virus, Maporal virus, Punta Toro virus, Rift Valley fever virus, San Angelo virus, Heartland virus, and SFTSV. The IC<sub>90</sub> of 2&#x02032;-FdC against SFTSV was 3.7 &#x003bc;M in an <italic>in vitro</italic> assay (<xref rid="T1" ref-type="table">Table 1</xref>). This value was much lower than that of ribavirin (49.7 &#x003bc;M) in the same study and favipiravir (22 &#x003bc;M) in the study conducted by Tani et al. (<xref rid="B63" ref-type="bibr">2016</xref>). In an <italic>in vivo</italic> study using IFNAR<sup>&#x02212;/&#x02212;</sup> mice, a 100 mg/kg/day treatment with 2&#x02032;-FdC was 100% protective against death caused by SFTSV (<xref rid="T2" ref-type="table">Table 2</xref>). However, all the mice treated with 2&#x02032;-FdC experienced substantial weight loss after SFTSV inoculation, whereas the favipiravir-treated mice displayed very little weight loss, suggesting that favipiravir was more effective than 2&#x02032;-FdC in controlling morbidity during the infection (Smee et al., <xref rid="B58" ref-type="bibr">2018</xref>). It was also found that treatments with 100 mg/kg/day of either 2&#x02032;-FdC or favipiravir significantly reduced the viral titers in the serum. Furthermore, there was a slight discrepancy both in the survival rates and virus titers between mice treated with 100 mg/kg/day of 2&#x02032;-FdC and those with 200 mg/kg/day of 2&#x02032;-FdC. The survival rate was 80 vs. 100% for 200- and 100-mg/kg/day treatments, respectively; and the virus titer in the serum of 200 mg/kg/day-treated mice was higher than that of mice receiving the 100-mg/kg/day treatment. It was speculated that this was caused by the limited sample size (<italic>n</italic> = 4 or 5).</p></sec><sec><title>Caffeic Acid</title><p>Caffeic Acid (CA) is a coffee-related polyphenol organic compound that can be found in various plants, including coffee beans. Single cup of coffee contains 70&#x02013;350 mg chlorogenic acid, the ester of caffeic acid (Clifford, <xref rid="B9" ref-type="bibr">1999</xref>). It exerts a variety of biological effects, including the suppression of cancer cells (Tang et al., <xref rid="B62" ref-type="bibr">2017</xref>; Bu&#x00142;dak et al., <xref rid="B6" ref-type="bibr">2018</xref>) and antiviral properties (Wang et al., <xref rid="B68" ref-type="bibr">2009</xref>; Utsunomiya et al., <xref rid="B67" ref-type="bibr">2014</xref>; Ding et al., <xref rid="B14" ref-type="bibr">2017</xref>; Langland et al., <xref rid="B34" ref-type="bibr">2018</xref>).</p><p>Ogawa et al. (<xref rid="B48" ref-type="bibr">2018</xref>) showed that CA dose-dependently inhibited SFTSV replication in an <italic>in vitro</italic> assay using Huh7.5.1-8 cells, a highly permissive derivative of human hepatoma Huh7 cells. The IC<sub>50</sub> of CA against SFTSV was 48 &#x003bc;M, and its CC<sub>50</sub> was 7.6 mM (<xref rid="T1" ref-type="table">Table 1</xref>). Interestingly, pretreatment of SFTSV with CA prior to inoculation effectively reduced the virus copy number in the supernatant of infected cells at 72 h post infection, and the inhibitory effect was significantly reduced when the cells were treated with CA after SFTSV inoculation. Thus, the authors speculated that CA mainly acted on the viral particles or influenced the early stages of SFTSV infection, although it could act on the host cells to inhibit viral genome replication.</p></sec><sec><title>Amodiaquine</title><p>Amodiaquine is a novel compound that is routinely prescribed as an antimalarial drug is reported to show antiviral effects against ebolavirus (Gignoux et al., <xref rid="B19" ref-type="bibr">2016</xref>; Sakurai et al., <xref rid="B53" ref-type="bibr">2018</xref>), dengue virus (Boonyasuppayakorn et al., <xref rid="B5" ref-type="bibr">2014</xref>), and zika virus (Balasubramanian et al., <xref rid="B3" ref-type="bibr">2017</xref>). The mechanism of inhibitory activity of amodiaquine against malaria and those viruses remains unclear.</p><p>Baba et al. (<xref rid="B1" ref-type="bibr">2017</xref>) investigated the effect of amodiaquine and other halogen molecules (fluorine, bromine, and iodine) against the replication of SFTSV <italic>in vitro</italic>. All the derivatives also displayed anti-SFTSV activity, and the IC<sub>50</sub> was 36.6, 31.1, and 15.6 &#x003bc;M for fluorine bromine, and iodine, respectively (<xref rid="T1" ref-type="table">Table 1</xref>). Among the compounds tested, amodiaquine was identified as a selective inhibitor against SFTSV replication. The CC<sub>50</sub> and the IC<sub>50</sub> of amodiaquine was &#x0003e;100 and 19.1 &#x003bc;M, respectively. The IC<sub>50</sub> of amodiaquine was lower than those of ribavirin (40.1 &#x003bc;M) and favipiravir (25.0 &#x003bc;M).</p></sec><sec><title>IFN-&#x003b3;</title><p>IFN-&#x003b3; is the only member of type II IFNs. It stimulates macrophage and dendritic cells to induce direct antimicrobial activities by regulating antigen processing and presentation pathways. It was initially thought that activated T cells and activated natural killer cells were the only relevant source of IFN-&#x003b3;; however, macrophages and dendritic cells can also be stimulated to produce IFN-&#x003b3; <italic>in vitro</italic> under certain conditions (Th&#x000e4;le and Kiderlen, <xref rid="B65" ref-type="bibr">2005</xref>). Because IFN-&#x003b3; can directly stimulate the expression of some potential antiviral IFN-stimulating proteins by the STAT1 signaling, it plays an important role in viral infection.</p><p>Ning et al. (<xref rid="B46" ref-type="bibr">2019</xref>) used enzyme-linked immunosorbent assays to demonstrate that SFTSV infection caused a substantial production of serum IFN-&#x003b3; in patients with SFTS. In turn, IFN-&#x003b3; exhibited a robust anti-SFTSV activity in cultured cells. Thereafter, they evaluated the efficacy of IFN-&#x003b3; as an anti-SFTSV drug <italic>in vivo</italic> in a suckling mouse model, which showed that IFN-&#x003b3; treatment prior to SFTSV infection significantly reduced mortality, protecting ~25% of animals from death, whereas all the untreated mice died within 13 days of the SFTSV challenge. When IFN-&#x003b3; was administrated post SFTSV infection, 100% of the mice died from the virus.</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Since then, a considerable number of studies regarding its epidemiological and virological characteristics have been conducted. Ribavirin, one of a broad-spectrum antiviral drug (Beaucourt and Vignuzzi, <xref rid="B4" ref-type="bibr">2014</xref>), is recommended for patients with SFTS in China, and it has been used to treat a considerable number of patients (Ministry of Health People's Republic of China, <xref rid="B43" ref-type="bibr">2011</xref>). The <italic>in vitro</italic> and <italic>in vivo</italic> studies on ribavirin (Shimojima et al., <xref rid="B57" ref-type="bibr">2014</xref>, <xref rid="B56" ref-type="bibr">2015</xref>; Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>; Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>; Lee et al., <xref rid="B36" ref-type="bibr">2017</xref>) showed the considerable effect. The results of the clinical study conducted by Liu et al. (<xref rid="B39" ref-type="bibr">2013</xref>), which showed that ribavirin did not reduce the fatality rate of patients with SFTS, discouraged us from considering ribavirin treatment for treating patients with SFTS. However, Li et al. (<xref rid="B37" ref-type="bibr">2018</xref>) reported that ribavirin is effective for early-stage patients with a low viral titer or for the pretreatment of exposed individuals. Nevertheless, in cases of ribavirin administration, patients should be intensely monitored because of the possible adverse events induced by ribavirin such as anemia and hyperamylasemia (Lu et al., <xref rid="B41" ref-type="bibr">2015</xref>).</p><p>Favipiravir exhibited higher effectiveness than ribavirin in <italic>in vitro</italic> and <italic>in vivo</italic> studies (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>, <xref rid="B64" ref-type="bibr">2018</xref>). Meanwhile, favipiravir remained effective when it was used following SFTSV infection in animal models (Tani et al., <xref rid="B63" ref-type="bibr">2016</xref>, <xref rid="B64" ref-type="bibr">2018</xref>; Gowen et al., <xref rid="B22" ref-type="bibr">2017</xref>) indicating its potential as an effective drug for treating SFTS patient. Currently, clinical trials are underway to evaluate the efficacy of favipiravir for treating patients with SFTS in Japan (Cyranoski, <xref rid="B10" ref-type="bibr">2018</xref>; Spengler et al., <xref rid="B60" ref-type="bibr">2018</xref>). Besides, it would be desirable to use intravenous administration because SFTS patients with severe symptoms could have difficulty in taking drugs orally.</p><p>Hexachlorophene, an antibacterial compound, was found to be effective for SFTSV in <italic>in vitro</italic> screening using an FDA-approved drug library (Yuan et al., <xref rid="B77" ref-type="bibr">2019</xref>). Because hexachlorophene can cause acute and subacute neurotoxicity in laboratory animals and humans (Kimbrough, <xref rid="B31" ref-type="bibr">1973</xref>; Ramu et al., <xref rid="B50" ref-type="bibr">2016</xref>), further <italic>in vitro</italic> and <italic>in vivo</italic> studies must be conducted.</p><p>CCBs, which are used to control cardiovascular diseases, have demonstrated significant effects against SFTSV replication both <italic>in vitro</italic> and <italic>in vivo</italic> (Li et al., <xref rid="B38" ref-type="bibr">2019</xref>). Notably, retrospectively conducted clinical study suggested that nifedipine remarkably reduced the case fatality rate in SFTS patients (Li et al., <xref rid="B38" ref-type="bibr">2019</xref>). Although nifedipine is administrated consistently for patients with cardiac disease, these findings are valuable for developing potential CCB-based therapeutics for SFTS. It is considered that the efficacy of nifedipine in treating patients with SFTS should be evaluated in a prospective manner. For clinical use, careful consideration of the risk-to-benefit value to the patient would be required because an overdose of CCBs has a high-risk of side effects, such as edema, liver damage, and death. The dose used for <italic>in vivo</italic> mouse study (100 mg/kg/day) was extremely higher than the dose generally used for humans (~0.2&#x02013;1.5 mg/kg/day). Still, these findings indicated the potential therapeutic effect of CCB treatment in patients with SFTS.</p><p>2&#x02032;-FdC is considered a viable candidate therapeutic agent against SFTS. Although, 2&#x02032;-FdC was more effective than favipiravir <italic>in vitro, in vivo</italic> efficacy was less than that of favipiravir (Smee et al., <xref rid="B58" ref-type="bibr">2018</xref>). The administration protocol of 2&#x02032;-FdC should be considered in future studies.</p><p>CA shows inhibitory effects against SFTSV <italic>in vitro</italic>. Little is known about the mechanism of the action, but it was considered that CA interacts with the viral particles, showing inhibitory effects (Ogawa et al., <xref rid="B48" ref-type="bibr">2018</xref>). Because there are limited reports regarding antiviral effects of CA or chlorogenic acid <italic>in vivo</italic> (Wang et al., <xref rid="B68" ref-type="bibr">2009</xref>; Ding et al., <xref rid="B14" ref-type="bibr">2017</xref>), further studies are needed.</p><p>Baba et al. (<xref rid="B1" ref-type="bibr">2017</xref>) showed that amodiaquine and other halogen molecules effectively inhibited the propagation of SFTSV <italic>in vitro</italic>. Amodiaquine is widely used as an antimalarial drug and can be administered at a low cost. The efficacy of amodiaquine <italic>in vivo</italic> should be evaluated.</p><p>The anti-SFTSV efficacy of IFN-&#x003b3; both <italic>in vitro</italic> and <italic>in vivo</italic> (Ning et al., <xref rid="B46" ref-type="bibr">2019</xref>) was reported. Because IFN-&#x003b3; is an FDA-approved drug, it has been suggested as a candidate antiviral drug for SFTSV alone or in combination with other drugs (Shimojima et al., <xref rid="B56" ref-type="bibr">2015</xref>).</p><p>The efficacy of antibody-based treatment has been studied against SFTS disease. Generally, antibodies play a critical role in the treating a wide variety of viral diseases; such as acquired immunodeficiency syndrome (Ferrari et al., <xref rid="B16" ref-type="bibr">2016</xref>), diseases caused by ebola virus (Mendoza et al., <xref rid="B42" ref-type="bibr">2017</xref>) and influenza (Nachbagauer and Krammer, <xref rid="B44" ref-type="bibr">2017</xref>). Antibody drugs neutralize viruses or bind to the virion to enhance antigen uptake by cytotoxic T cells, making them highly specific for the target virus. It was reported that antiserum of a patient recovered from SFTS completely protected mice from the lethal infection of SFTSV (Shimada et al., <xref rid="B55" ref-type="bibr">2015</xref>). It was also shown that antibodies against SFTSV Gn protein significantly reduced the fatality rate in mice infected with SFTSV, even when treatment was initiated from 3 days post inoculation (Kim et al., <xref rid="B29" ref-type="bibr">2019</xref>). These reports suggested that antibodies alone or in combination with antiviral drugs could be used to treat patients with SFTS.</p><p>There are two studies for developing vaccines against SFTSV infection (Dong et al., <xref rid="B15" ref-type="bibr">2019</xref>; Kwak et al., <xref rid="B33" ref-type="bibr">2019</xref>). A recombinant vesicular stomatitis virus expressing SFTSV antigen completely protected mice from SFTSV infection (Dong et al., <xref rid="B15" ref-type="bibr">2019</xref>). A DNA vaccine expressing antigens of SFTSV, elicited both neutralizing antibody response and SFTSV-specific T cell response and protected aged-ferrets from the lethal SFTSV infection (Kwak et al., <xref rid="B33" ref-type="bibr">2019</xref>). Safe and effective vaccines against SFTS should be developed.</p><p>Because all these mentioned drugs have inhibitory effect on SFTSV replication, combination therapies with some drugs, which have different mechanisms of action should be considered. Although, it should be considered that an antiviral drug against SFTS would be administrated to a pre-symptomatic exposed individual, the main targets of these drugs are certainly patients with suggestive symptoms of SFTS. SFTSV circulates between mammals and ticks in Southeast Asia, indicating that we cannot escape the risk of being infected with SFTSV. SFTS is classified in a disease category of viral hemorrhagic fever with high case fatality rate. Recently, cases of SFTS have been reported, wherein the patients were infected with SFTSV from cats, which might be infected with SFTSV from tick (Kida et al., <xref rid="B28" ref-type="bibr">2019</xref>). Therefore, we are hopeful that specific treatments with antiviral agents will be developed and approved for patients with SFTS as early as possible.</p></sec><sec id="s4"><title>Author Contributions</title><p>MS and MT-I conceptualized and designed the study. MT-I collected and assembled the data and drafted the manuscript. MS critically revised the manuscript.</p><sec><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank all the staff members working for the research project for SFTS in Japan, especially, Dr. Hideki Tani, Dr. Masayuki Shimojima, Dr. Takeshi Kurosu, Dr. Tomoki Yoshikawa, Dr. Hirofumi Kato, Dr. Masaaki Satoh, Department of Virology 1, National Institute of Infectious Diseases, Tokyo, Japan. The present affiliate of Dr. Hideki Tani is the Department of Virology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> Some part of this review article was obtained through the studies financially supported from the Ministry of Health, Labour, and Welfare (grant number H25-Shinko-Shitei-009), Japan Agency for Medical Research and Development (AMED, 16fk0108002j, 17fk0108202j, 18fk0108002j, 19fk0108081j, 19fk0108072). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>M.</given-names></name><name><surname>Toyama</surname><given-names>M.</given-names></name><name><surname>Sakakibara</surname><given-names>N.</given-names></name><name><surname>Okamoto</surname><given-names>M.</given-names></name><name><surname>Arima</surname><given-names>N.</given-names></name><name><surname>Saijo</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors</article-title>. <source>Antivir. Chem. Chemother.</source>
<volume>25</volume>, <fpage>83</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1177/2040206617740303</pub-id><?supplied-pmid 29096526?><pub-id pub-id-type="pmid">29096526</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajramovic</surname><given-names>J. J.</given-names></name><name><surname>Volmer</surname><given-names>R.</given-names></name><name><surname>Syan</surname><given-names>S.</given-names></name><name><surname>Pochet</surname><given-names>S.</given-names></name><name><surname>Gonzalez-Dunia</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>). <article-title>2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>48</volume>, <fpage>1422</fpage>&#x02013;<lpage>1425</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.48.4.1422-1425.2004</pub-id><?supplied-pmid 15047559?><pub-id pub-id-type="pmid">15047559</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balasubramanian</surname><given-names>A.</given-names></name><name><surname>Teramoto</surname><given-names>T.</given-names></name><name><surname>Kulkarni</surname><given-names>A. A.</given-names></name><name><surname>Bhattacharjee</surname><given-names>A. K.</given-names></name><name><surname>Padmanabhan</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virus</article-title>. <source>Antiviral Res.</source>
<volume>137</volume>, <fpage>141</fpage>&#x02013;<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2016.11.015</pub-id><?supplied-pmid 27889529?><pub-id pub-id-type="pmid">27889529</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaucourt</surname><given-names>S.</given-names></name><name><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance</article-title>. <source>Curr. Opin. Virol.</source>
<volume>8</volume>, <fpage>10</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.04.011</pub-id><?supplied-pmid 24846716?><pub-id pub-id-type="pmid">24846716</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonyasuppayakorn</surname><given-names>S.</given-names></name><name><surname>Reichert</surname><given-names>E. D.</given-names></name><name><surname>Manzano</surname><given-names>M.</given-names></name><name><surname>Nagarajan</surname><given-names>K.</given-names></name><name><surname>Padmanabhan</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity</article-title>. <source>Antiviral Res.</source>
<volume>106</volume>, <fpage>125</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2014.03.014</pub-id><?supplied-pmid 24680954?><pub-id pub-id-type="pmid">24680954</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu&#x00142;dak</surname><given-names>R. J.</given-names></name><name><surname>Hejmo</surname><given-names>T.</given-names></name><name><surname>Osowski</surname><given-names>M.</given-names></name><name><surname>Bu&#x00142;dak</surname><given-names>&#x00141;.</given-names></name><name><surname>Kukla</surname><given-names>M.</given-names></name><name><surname>Polaniak</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The impact of coffee and its selected bioactive compounds on the development and progression of colorectal cancer <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source>Molecules</source>
<volume>23</volume>:<fpage>E3309</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23123309</pub-id><?supplied-pmid 30551667?><pub-id pub-id-type="pmid">30551667</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X. P.</given-names></name><name><surname>Cong</surname><given-names>M. L.</given-names></name><name><surname>Li</surname><given-names>M. H.</given-names></name><name><surname>Kang</surname><given-names>Y. J.</given-names></name><name><surname>Feng</surname><given-names>Y. M.</given-names></name><name><surname>Plyusnin</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Infection and pathogenesis of Huaiyangshan virus (a novel tick-borne bunyavirus) in laboratory rodents</article-title>. <source>J. Gen. Virol.</source>
<volume>93</volume>, <fpage>1288</fpage>&#x02013;<lpage>1293</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.041053-0</pub-id><?supplied-pmid 22357748?><pub-id pub-id-type="pmid">22357748</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S. J.</given-names></name><name><surname>Park</surname><given-names>S. W.</given-names></name><name><surname>Bae</surname><given-names>I. G.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Ryu</surname><given-names>S. Y.</given-names></name><name><surname>Kim</surname><given-names>H. A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Severe fever with thrombocytopenia syndrome in South Korea, 2013-2015</article-title>. <source>PLoS Negl. Trop. Dis.</source>
<volume>10</volume>:<fpage>e0005264</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005264</pub-id><?supplied-pmid 28033338?><pub-id pub-id-type="pmid">28033338</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname><given-names>M. N.</given-names></name></person-group> (<year>1999</year>). <article-title>Chlorogenic acids and other cinnamates&#x02013; nature, occurrence and dietary burden</article-title>. <source>J. Sci. Food. Agric.</source>
<volume>79</volume>:<fpage>362</fpage>&#x02013;<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1097-0010(19990301)79:3&#x0003c;362::AID-JSFA256&#x0003e;3.0.CO;2-D</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>East Asia braces for surge in deadly tick-borne virus news</article-title>. <source>Nature</source>
<volume>556</volume>, <fpage>282</fpage>&#x02013;<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-018-04486-6</pub-id><pub-id pub-id-type="pmid">29666487</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Clercq</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Approved antiviral drugs over the past 50 years</article-title>. <source>Clin. Microbiol. Rev.</source>
<volume>29</volume>, <fpage>695</fpage>&#x02013;<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00102-15</pub-id><?supplied-pmid 27281742?><pub-id pub-id-type="pmid">27281742</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delang</surname><given-names>L.</given-names></name><name><surname>Guerrero</surname><given-names>N. S.</given-names></name><name><surname>Tas</surname><given-names>A.</given-names></name><name><surname>Qu&#x000e9;rat</surname><given-names>G.</given-names></name><name><surname>Pastorino</surname><given-names>B.</given-names></name><name><surname>Froeyen</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>69</volume>, <fpage>2770</fpage>&#x02013;<lpage>2784</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dku209</pub-id><?supplied-pmid 24951535?><pub-id pub-id-type="pmid">24951535</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewald</surname><given-names>L. E.</given-names></name><name><surname>Dyall</surname><given-names>J.</given-names></name><name><surname>Sword</surname><given-names>J. M.</given-names></name><name><surname>Torzewski</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Postnikova</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The calcium channel blocker bepridil demonstrates efficacy in the murine model of marburg virus disease</article-title>. <source>J. Infect. Dis.</source>
<volume>22</volume>, <fpage>S588</fpage>&#x02013;<lpage>S591</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiy332</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/srep45723</pub-id><?supplied-pmid 28393840?><pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Qi</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus</article-title>. <source>NPJ Vaccines</source>
<volume>4</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-018-0096-y</pub-id><?supplied-pmid 30701094?><pub-id pub-id-type="pmid">30701094</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>G.</given-names></name><name><surname>Haynes</surname><given-names>B. F.</given-names></name><name><surname>Koenig</surname><given-names>S.</given-names></name><name><surname>Nordstrom</surname><given-names>J. L.</given-names></name><name><surname>Margolis</surname><given-names>D. M.</given-names></name><name><surname>Tomaras</surname><given-names>G. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>15</volume>, <fpage>823</fpage>&#x02013;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2016.173</pub-id><?supplied-pmid 27725635?><pub-id pub-id-type="pmid">27725635</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Shiraki</surname><given-names>K.</given-names></name><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Barnard</surname><given-names>D. L.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections</article-title>. <source>Antiviral Res.</source>
<volume>82</volume>, <fpage>95</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.02.198</pub-id><?supplied-pmid 19428599?><pub-id pub-id-type="pmid">19428599</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gai</surname><given-names>Z.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>S. W.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Person-to-person transmission of severe fever with thrombocytopenia syndrome bunyavirus through blood contact</article-title>. <source>Clin. Infect. Dis.</source>
<volume>54</volume>, <fpage>249</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir776</pub-id><?supplied-pmid 22095565?><pub-id pub-id-type="pmid">22095565</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gignoux</surname><given-names>E.</given-names></name><name><surname>Azman</surname><given-names>A. S.</given-names></name><name><surname>De Smet</surname><given-names>M.</given-names></name><name><surname>Azuma</surname><given-names>P.</given-names></name><name><surname>Massaquoi</surname><given-names>M.</given-names></name><name><surname>Job</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Effect of artesunate.amodiaquine on mortality related to Ebola virus disease</article-title>. <source>N. Engl. J. Med.</source>
<volume>374</volume>, <fpage>23</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1504605</pub-id><?supplied-pmid 26735991?><pub-id pub-id-type="pmid">26735991</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhill</surname><given-names>D. H.</given-names></name><name><surname>Te Velthuis</surname><given-names>A. J. W.</given-names></name><name><surname>Fletcher</surname><given-names>R. A.</given-names></name><name><surname>Langat</surname><given-names>P.</given-names></name><name><surname>Zambon</surname><given-names>M.</given-names></name><name><surname>Lackenby</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The mechanism of resistance to favipiravir in influenza</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>115</volume>, <fpage>11613</fpage>&#x02013;<lpage>11618</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1811345115</pub-id><?supplied-pmid 30352857?><pub-id pub-id-type="pmid">30352857</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowen</surname><given-names>B. B.</given-names></name><name><surname>Hickerson</surname><given-names>B. T.</given-names></name></person-group> (<year>2017</year>). <article-title>Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies</article-title>. <source>J. Microbiol.</source>
<volume>55</volume>, <fpage>183</fpage>&#x02013;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-017-7029-8</pub-id><?supplied-pmid 28243938?><pub-id pub-id-type="pmid">28243938</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gowen</surname><given-names>B. B.</given-names></name><name><surname>Westover</surname><given-names>J. B.</given-names></name><name><surname>Miao</surname><given-names>J.</given-names></name><name><surname>Van Wettere</surname><given-names>A. J.</given-names></name><name><surname>Rigas</surname><given-names>J. D.</given-names></name><name><surname>Hickerson</surname><given-names>B. T.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Modeling severe fever with thrombocytopenia syndrome virus infection in golden syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir</article-title>. <source>J. Virol.</source>
<volume>91</volume>, <fpage>e01942</fpage>&#x02013;<lpage>e01916</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01942-16</pub-id><?supplied-pmid 27881648?><pub-id pub-id-type="pmid">27881648</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graci</surname><given-names>J. D.</given-names></name><name><surname>Cameron</surname><given-names>C. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Mechanisms of action of ribavirin against distinct viruses</article-title>. <source>Rev. Med. Virol.</source>
<volume>16</volume>, <fpage>37</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.483</pub-id><?supplied-pmid 16287208?><pub-id pub-id-type="pmid">16287208</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>J. T. A.</given-names></name><name><surname>Kuo</surname><given-names>C. J.</given-names></name><name><surname>Hsieh</surname><given-names>H. P.</given-names></name><name><surname>Wang</surname><given-names>Y. C.</given-names></name><name><surname>Huang</surname><given-names>K. K.</given-names></name><name><surname>Lin</surname><given-names>C. P. C.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV</article-title>. <source>FEBS Lett.</source>
<volume>574</volume>, <fpage>116</fpage>&#x02013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2004.08.015</pub-id><?supplied-pmid 15358550?><pub-id pub-id-type="pmid">15358550</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>SFTS virus infection in nonhuman primates</article-title>. <source>J. Infect. Dis.</source>
<volume>211</volume>, <fpage>915</fpage>&#x02013;<lpage>925</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiu564</pub-id><?supplied-pmid 25326554?><pub-id pub-id-type="pmid">25326554</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Ning</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>109</volume>, <fpage>10053</fpage>&#x02013;<lpage>10058</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1120246109</pub-id><?supplied-pmid 22665769?><pub-id pub-id-type="pmid">22665769</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Yamagishi</surname><given-names>T.</given-names></name><name><surname>Shimada</surname><given-names>T.</given-names></name><name><surname>Matsui</surname><given-names>T.</given-names></name><name><surname>Shimojima</surname><given-names>M.</given-names></name><name><surname>Saijo</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013-2014</article-title>. <source>PLoS ONE</source>
<volume>11</volume>:<fpage>e0165207</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0165207</pub-id><?supplied-pmid 27776187?><pub-id pub-id-type="pmid">27776187</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kida</surname><given-names>K.</given-names></name><name><surname>Matsuoka</surname><given-names>Y.</given-names></name><name><surname>Shimoda</surname><given-names>T.</given-names></name><name><surname>Matsuoka</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>A case of cat-to-human transmission of severe fever with thrombocytopenia syndrome virus</article-title>. <source>Jpn. J. Infect. Dis.</source>
<volume>72</volume>, <fpage>356</fpage>&#x02013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.7883/yoken.JJID.2018.526</pub-id><?supplied-pmid 31366857?><pub-id pub-id-type="pmid">31366857</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K. H.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Ko</surname><given-names>M.</given-names></name><name><surname>Chun</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus</article-title>. <source>PLoS Pathog.</source>
<volume>15</volume>:<fpage>e1007375</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1007375</pub-id><?supplied-pmid 30707748?><pub-id pub-id-type="pmid">30707748</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K. H.</given-names></name><name><surname>Yi</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>G.</given-names></name><name><surname>Choi</surname><given-names>S. J.</given-names></name><name><surname>Jun</surname><given-names>K. I.</given-names></name><name><surname>Kim</surname><given-names>N. H.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Severe fever with thrombocytopenia syndrome, South Korea, 2012</article-title>. <source>Emerg. Infect. Dis.</source>
<volume>19</volume>, <fpage>1892</fpage>&#x02013;<lpage>1894</lpage>
<pub-id pub-id-type="doi">10.3201/eid1911.130792</pub-id><?supplied-pmid 24206586?><pub-id pub-id-type="pmid">24206586</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimbrough</surname><given-names>R. D.</given-names></name></person-group> (<year>1973</year>). <article-title>Review of the toxicity of hexachlorophene, including its neurotoxicity</article-title>. <source>J. Clini. Pharmacol.</source>
<volume>13</volume>, <fpage>439</fpage>&#x02013;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1002/j.1552-4604.1973.tb00196.x</pub-id><?supplied-pmid 4206035?><pub-id pub-id-type="pmid">4206035</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumaki</surname><given-names>Y.</given-names></name><name><surname>Day</surname><given-names>C. W.</given-names></name><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Morrey</surname><given-names>J. D.</given-names></name><name><surname>Barnard</surname><given-names>D. L.</given-names></name></person-group> (<year>2011</year>). <article-title><italic>In vitro</italic> and <italic>in vivo</italic> efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections</article-title>. <source>Antiviral Res.</source>
<volume>92</volume>, <fpage>329</fpage>&#x02013;<lpage>340</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2011.09.001</pub-id><?supplied-pmid 21925541?><pub-id pub-id-type="pmid">21925541</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>J. E.</given-names></name><name><surname>Kim</surname><given-names>Y. I.</given-names></name><name><surname>Park</surname><given-names>S. J.</given-names></name><name><surname>Yu</surname><given-names>M. A.</given-names></name><name><surname>Kwon</surname><given-names>H. I.</given-names></name><name><surname>Eo</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets</article-title>. <source>Nat. Commun</source>. <volume>10</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-11815-4</pub-id><?supplied-pmid 31444366?><pub-id pub-id-type="pmid">30602773</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langland</surname><given-names>J.</given-names></name><name><surname>Jacobs</surname><given-names>B.</given-names></name><name><surname>Wagner</surname><given-names>C. E.</given-names></name><name><surname>Ruiz</surname><given-names>G.</given-names></name><name><surname>Cahill</surname><given-names>T. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Antiviral activity of metal chelates of caffeic acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and vaccinia viruses</article-title>. <source>Antiviral Res.</source>
<volume>160</volume>, <fpage>143</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.021</pub-id><?supplied-pmid 30393014?><pub-id pub-id-type="pmid">30393014</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavanya</surname><given-names>M.</given-names></name><name><surname>Cuevas</surname><given-names>C. D.</given-names></name><name><surname>Thomas</surname><given-names>M.</given-names></name><name><surname>Cherry</surname><given-names>S.</given-names></name><name><surname>Ross</surname><given-names>S. R.</given-names></name></person-group> (<year>2013</year>). <article-title>siRNA screen for genes that affect Jun&#x000ed;n virus entry uncovers voltage-gated calcium channels as a therapeutic target</article-title>. <source>Sci. Transl. Med.</source>
<volume>5</volume>:<fpage>204r</fpage>a131. <pub-id pub-id-type="doi">10.1126/scitranslmed.3006827</pub-id><?supplied-pmid 24068738?><pub-id pub-id-type="pmid">24068738</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M. J.</given-names></name><name><surname>Kim</surname><given-names>K. H.</given-names></name><name><surname>Yi</surname><given-names>J.</given-names></name><name><surname>Choi</surname><given-names>S. J.</given-names></name><name><surname>Choe</surname><given-names>P. G.</given-names></name><name><surname>Park</surname><given-names>W. B.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title><italic>In vitro</italic> antiviral activity of ribavirin against severe fever with thrombocytopenia syndrome virus</article-title>. <source>Korean J. Intern. Med.</source>
<volume>32</volume>, <fpage>731</fpage>&#x02013;<lpage>737</lpage>. <pub-id pub-id-type="doi">10.3904/kjim.2016.109</pub-id><?supplied-pmid 27899013?><pub-id pub-id-type="pmid">27899013</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Bin</surname><given-names>X. B.</given-names></name><name><surname>Zhang</surname><given-names>S. F.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011&#x02013;17: a prospective observational study</article-title>. <source>Lancet Infect. Dis.</source>
<volume>18</volume>, <fpage>1127</fpage>&#x02013;<lpage>1137</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30293-7</pub-id><?supplied-pmid 30054190?><pub-id pub-id-type="pmid">30054190</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L. K.</given-names></name><name><surname>Li</surname><given-names>S. F.</given-names></name><name><surname>Zhang</surname><given-names>S. F.</given-names></name><name><surname>Wan</surname><given-names>W. W.</given-names></name><name><surname>Zhang</surname><given-names>Y. L.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality</article-title>. <source>Cell Res.</source>
<volume>29</volume>, <fpage>739</fpage>&#x02013;<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-019-0214-z</pub-id><?supplied-pmid 31444469?><pub-id pub-id-type="pmid">31444469</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Q. B.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>L. Y.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome</article-title>. <source>Clin. Infect. Dis.</source>
<volume>57</volume>, <fpage>1292</fpage>&#x02013;<lpage>1299</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit530</pub-id><?supplied-pmid 23965284?><pub-id pub-id-type="pmid">23965284</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Paessler</surname><given-names>S.</given-names></name><name><surname>Walker</surname><given-names>D. H.</given-names></name><name><surname>Tesh</surname><given-names>R. B.</given-names></name><name><surname>Yu</surname><given-names>X. J.</given-names></name></person-group> (<year>2014</year>). <article-title>The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic fever</article-title>. <source>J. Virol.</source>
<volume>88</volume>, <fpage>1781</fpage>&#x02013;<lpage>1786</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02277-13</pub-id><?supplied-pmid 24257618?><pub-id pub-id-type="pmid">24257618</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q. B.</given-names></name><name><surname>Zhang</surname><given-names>S. Y.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Hu</surname><given-names>J. G.</given-names></name><name><surname>Fan</surname><given-names>Y. D.</given-names></name><name><surname>Guo</surname><given-names>C. T.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Common adverse events associated with ribavirin therapy for Severe fever with thrombocytopenia syndrome</article-title>. <source>Antiviral Res.</source>
<volume>119</volume>, <fpage>19</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.04.006</pub-id><?supplied-pmid 25892251?><pub-id pub-id-type="pmid">25892251</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>E. J.</given-names></name><name><surname>Racine</surname><given-names>T.</given-names></name><name><surname>Kobinger</surname><given-names>G. P.</given-names></name></person-group> (<year>2017</year>). <article-title>The ongoing evolution of antibody-based treatments for Ebola virus infection</article-title>. <source>Immunotherapy</source>. <volume>9</volume>, <fpage>435</fpage>&#x02013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.2217/imt-2017-0010</pub-id><?supplied-pmid 28357917?><pub-id pub-id-type="pmid">28357917</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Ministry of Health and People's Republic of China</collab></person-group> (<year>2011</year>). <article-title>Guideline for prevention and treatment of severe fever with thrombocytopenia syndrome (2010 version)</article-title>. <source>Chinese J. Clin. Infect. Dis.</source>
<volume>4</volume>, <fpage>193</fpage>&#x02212;<lpage>194</lpage>.</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachbagauer</surname><given-names>R.</given-names></name><name><surname>Krammer</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Universal influenza virus vaccines and therapeutic antibodies</article-title>. <source>Clin. Microbiol. Infect.</source>
<volume>23</volume>, <fpage>222</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2017.02.009</pub-id><?supplied-pmid 28216325?><pub-id pub-id-type="pmid">28216325</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>S.</given-names></name><name><surname>Azuma</surname><given-names>M.</given-names></name><name><surname>Maruhashi</surname><given-names>T.</given-names></name><name><surname>Sogabe</surname><given-names>K.</given-names></name><name><surname>Sumitani</surname><given-names>R.</given-names></name><name><surname>Uemura</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome</article-title>. <source>J. Infect. Chemother.</source>
<volume>24</volume>, <fpage>389</fpage>&#x02013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiac.2017.11.004</pub-id><?supplied-pmid 29428565?><pub-id pub-id-type="pmid">29428565</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Y.</given-names></name><name><surname>Mo</surname><given-names>Q.</given-names></name><name><surname>Feng</surname><given-names>K.</given-names></name><name><surname>Min</surname><given-names>Y. Q.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Hou</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Interferon-&#x003b3;-directed inhibition of a novel high-pathogenic phlebovirus and viral antagonism of the antiviral signaling by targeting STAT1</article-title>. <source>Front. Immunol.</source>
<volume>10</volume>:<fpage>1182</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.01182</pub-id><?supplied-pmid 31191546?><pub-id pub-id-type="pmid">31191546</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>M.</given-names></name><name><surname>Yin</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Severe fever with thrombocytopenia syndrome virus among domesticated animals, China</article-title>. <source>Emerg. Infect. Dis.</source>
<volume>19</volume>, <fpage>756</fpage>&#x02013;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.3201/eid1905.120245</pub-id><?supplied-pmid 23648209?><pub-id pub-id-type="pmid">23648209</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>M.</given-names></name><name><surname>Shirasago</surname><given-names>Y.</given-names></name><name><surname>Ando</surname><given-names>S.</given-names></name><name><surname>Shimojima</surname><given-names>M.</given-names></name><name><surname>Saijo</surname><given-names>M.</given-names></name><name><surname>Fukasawa</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Caffeic acid, a coffee-related organic acid, inhibits infection by severe fever with thrombocytopenia syndrome virus <italic>in vitro</italic></article-title>. <source>J. Infect. Chemother.</source>
<volume>24</volume>, <fpage>597</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiac.2018.03.005</pub-id><?supplied-pmid 29628386?><pub-id pub-id-type="pmid">29628386</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>W. S.</given-names></name><name><surname>Heo</surname><given-names>S. T.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Choi</surname><given-names>W. J.</given-names></name><name><surname>Han</surname><given-names>M. G.</given-names></name><name><surname>Kim</surname><given-names>J. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome</article-title>. <source>Int. J. Infect. Dis.</source>
<volume>18</volume>, <fpage>84</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.08.011</pub-id><?supplied-pmid 24161209?><pub-id pub-id-type="pmid">24161209</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramu</surname><given-names>J.</given-names></name><name><surname>Konak</surname><given-names>T.</given-names></name><name><surname>Paule</surname><given-names>M. G.</given-names></name><name><surname>Hanig</surname><given-names>J. P.</given-names></name><name><surname>Liachenko</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Longitudinal diffusion tensor imaging of the rat brain after hexachlorophene exposure</article-title>. <source>Neurotoxicology</source>
<volume>56</volume>, <fpage>225</fpage>&#x02013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuro.2016.08.011</pub-id><?supplied-pmid 27555423?><pub-id pub-id-type="pmid">27555423</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saijo</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy</article-title>. <source>J. Infect. Chemother.</source>
<volume>24</volume>, <fpage>773</fpage>&#x02013;<lpage>781</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiac.2018.07.009</pub-id><?supplied-pmid 30098914?><pub-id pub-id-type="pmid">30098914</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Kolokoltsov</surname><given-names>A. A.</given-names></name><name><surname>Chen</surname><given-names>C. C.</given-names></name><name><surname>Tidwell</surname><given-names>M. W.</given-names></name><name><surname>Bauta</surname><given-names>W. E.</given-names></name><name><surname>Klugbauer</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment</article-title>. <source>Science</source>. <volume>347</volume>, <fpage>995</fpage>&#x02013;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1126/science.1258758</pub-id><?supplied-pmid 25722412?><pub-id pub-id-type="pmid">25722412</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>Y.</given-names></name><name><surname>Sakakibara</surname><given-names>N.</given-names></name><name><surname>Toyama</surname><given-names>M.</given-names></name><name><surname>Baba</surname><given-names>M.</given-names></name><name><surname>Davey</surname><given-names>R. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Novel amodiaquine derivatives potently inhibit Ebola virus infection</article-title>. <source>Antiviral Res.</source>
<volume>160</volume>, <fpage>175</fpage>&#x02013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.025</pub-id><?supplied-pmid 30395872?><pub-id pub-id-type="pmid">30395872</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherbik</surname><given-names>S. V.</given-names></name><name><surname>Brinton</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Virus-induced Ca<sup>2+</sup> influx extends survival of west nile virus-infected cells</article-title>. <source>J. Virol.</source>
<volume>84</volume>, <fpage>8721</fpage>&#x02013;<lpage>8731</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00144-10</pub-id><?supplied-pmid 20538858?><pub-id pub-id-type="pmid">20538858</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>S.</given-names></name><name><surname>Posadas</surname><given-names>H. G.</given-names></name><name><surname>Aoki</surname><given-names>K.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Hayasaka</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection</article-title>. <source>Virology</source>
<volume>482</volume>, <fpage>19</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.03.010</pub-id><?supplied-pmid 25817401?><pub-id pub-id-type="pmid">25817401</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimojima</surname><given-names>M.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Taniguchi</surname><given-names>S.</given-names></name><name><surname>Fukuma</surname><given-names>A.</given-names></name><name><surname>Saijo</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection</article-title>. <source>Virol. J.</source>
<volume>12</volume>:<fpage>181</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-015-0412-3</pub-id><?supplied-pmid 26527529?><pub-id pub-id-type="pmid">26527529</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimojima</surname><given-names>M.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name><name><surname>Fukuma</surname><given-names>A.</given-names></name><name><surname>Taniguchi</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Effects of ribavirin on severe fever with thrombocytopenia syndrome virus <italic>in vitro</italic></article-title>. <source>Jpn. J. Infect. Dis.</source>
<volume>67</volume>, <fpage>423</fpage>&#x02013;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.7883/yoken.67.423</pub-id><?supplied-pmid 25410555?><pub-id pub-id-type="pmid">25410555</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>D. F.</given-names></name><name><surname>Jung</surname><given-names>K. H.</given-names></name><name><surname>Westover</surname><given-names>J.</given-names></name><name><surname>Gowen</surname><given-names>B. B.</given-names></name></person-group> (<year>2018</year>). <article-title>2&#x02032;-Fluoro-2&#x02032;-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses <italic>in vitro</italic> and in phleboviral disease mouse models</article-title>. <source>Antiviral Res.</source>
<volume>160</volume>, <fpage>48</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2018.10.013</pub-id><?supplied-pmid 30339848?><pub-id pub-id-type="pmid">30339848</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snell</surname><given-names>N. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Ribavirin - current status of a broad spectrum antiviral agent</article-title>. <source>Expert Opin. Pharmacother.</source>
<volume>2</volume>, <fpage>1317</fpage>&#x02013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1517/14656566.2.8.1317</pub-id><?supplied-pmid 11585000?><pub-id pub-id-type="pmid">11585000</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spengler</surname><given-names>J. R.</given-names></name><name><surname>Bente</surname><given-names>D. A.</given-names></name><name><surname>Bray</surname><given-names>M.</given-names></name><name><surname>Burt</surname><given-names>F.</given-names></name><name><surname>Hewson</surname><given-names>R.</given-names></name><name><surname>Korukluoglu</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Second international conference on Crimean-Congo hemorrhagic fever</article-title>. <source>Antiviral Res.</source>
<volume>150</volume>, <fpage>137</fpage>&#x02013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.11.019</pub-id><?supplied-pmid 29199036?><pub-id pub-id-type="pmid">29199036</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Maeda</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Ishido</surname><given-names>A.</given-names></name><name><surname>Shigeoka</surname><given-names>T.</given-names></name><name><surname>Tominaga</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan</article-title>. <source>J. Infect. Dis.</source>
<volume>209</volume>, <fpage>816</fpage>&#x02013;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit603</pub-id><?supplied-pmid 24231186?><pub-id pub-id-type="pmid">24231186</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zuo</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Anti-colon cancer effect of caffeic acid p-nitro-phenethyl ester <italic>in vitro</italic> and <italic>in vivo</italic> and detection of its metabolites</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>:<fpage>7599</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-07953-8</pub-id><?supplied-pmid 28790461?><pub-id pub-id-type="pmid">28790461</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Fukuma</surname><given-names>A.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Taniguchi</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name><name><surname>Iwata-yoshikawa</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus</article-title>. <source>mSphere</source>
<volume>1</volume>, <fpage>e00061</fpage>&#x02013;<lpage>e00015</lpage>. <pub-id pub-id-type="doi">10.1128/mSphere.00061-15</pub-id><?supplied-pmid 27303697?><pub-id pub-id-type="pmid">27303697</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>H.</given-names></name><name><surname>Komeno</surname><given-names>T.</given-names></name><name><surname>Fukuma</surname><given-names>A.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Taniguchi</surname><given-names>S.</given-names></name><name><surname>Shimojima</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration</article-title>. <source>PLoS ONE</source>
<volume>13</volume>:<fpage>e0206416</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0206416</pub-id><?supplied-pmid 30365543?><pub-id pub-id-type="pmid">30365543</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Th&#x000e4;le</surname><given-names>C.</given-names></name><name><surname>Kiderlen</surname><given-names>A. F.</given-names></name></person-group> (<year>2005</year>). <article-title>Sources of interferon-gamma (IFN-&#x003b3;) in early immune response to Listeria monocytogenes</article-title>. <source>Immunobiology</source>
<volume>210</volume>, <fpage>673</fpage>&#x02013;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2005.07.003</pub-id><?supplied-pmid 16323704?><pub-id pub-id-type="pmid">16323704</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>X. C.</given-names></name><name><surname>Yun</surname><given-names>Y.</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Van Kim</surname><given-names>S. H.</given-names></name><name><surname>Thao</surname><given-names>N. T. P.</given-names></name><name><surname>Man</surname><given-names>P. K. C.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Endemic severe fever with thrombocytopenia syndrome, Vietnam</article-title>. <source>Emerg. Infect. Dis.</source>
<volume>25</volume>, <fpage>1029</fpage>&#x02013;<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.3201/eid2505.181463</pub-id><?supplied-pmid 31002059?><pub-id pub-id-type="pmid">31002059</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsunomiya</surname><given-names>H.</given-names></name><name><surname>Ichinose</surname><given-names>M.</given-names></name><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Uozaki</surname><given-names>M.</given-names></name><name><surname>Morishita</surname><given-names>J.</given-names></name><name><surname>Kuwahara</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Inhibition by caffeic acid of the influenza a virus multiplication <italic>in vitro</italic></article-title>. <source>Int. J. Mol. Med.</source>
<volume>34</volume>, <fpage>1020</fpage>&#x02013;<lpage>1024</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2014.1859</pub-id><?supplied-pmid 25050906?><pub-id pub-id-type="pmid">25050906</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G. F.</given-names></name><name><surname>Shi</surname><given-names>L. P.</given-names></name><name><surname>Ren</surname><given-names>Y. D.</given-names></name><name><surname>Liu</surname><given-names>Q. F.</given-names></name><name><surname>Liu</surname><given-names>H. F.</given-names></name><name><surname>Zhang</surname><given-names>R. J.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source>Antiviral Res.</source>
<volume>83</volume>, <fpage>186</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.05.002</pub-id><?supplied-pmid 19463857?><pub-id pub-id-type="pmid">19463857</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Screening of FDA-approved drugs for inhibitors of Japanese encephalitis virus infection</article-title>. <source>J. Virol.</source>
<volume>91</volume>, <fpage>e01055</fpage>&#x02013;<lpage>e01017</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01055-17</pub-id><?supplied-pmid 28814523?><pub-id pub-id-type="pmid">28814523</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>S. R.</given-names></name><name><surname>Guerrero</surname><given-names>L. W.</given-names></name><name><surname>Chakrabarti</surname><given-names>A. K.</given-names></name><name><surname>McMullan</surname><given-names>L. K.</given-names></name><name><surname>Flint</surname><given-names>M.</given-names></name><name><surname>Bluemling</surname><given-names>G. R.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems</article-title>. <source>Antiviral Res.</source>
<volume>136</volume>, <fpage>9</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.10.007</pub-id><?supplied-pmid 27771389?><pub-id pub-id-type="pmid">27771389</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>S. R.</given-names></name><name><surname>Scholte</surname><given-names>F. E. M.</given-names></name><name><surname>Flint</surname><given-names>M.</given-names></name><name><surname>Chatterjee</surname><given-names>P.</given-names></name><name><surname>Nichol</surname><given-names>S. T.</given-names></name><name><surname>Bergeron</surname><given-names>&#x000c9;.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Identification of 2&#x02032;-deoxy-2&#x02032;-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus</article-title>. <source>Antiviral Res.</source>
<volume>147</volume>, <fpage>91</fpage>&#x02013;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.10.008</pub-id><?supplied-pmid 29024765?><pub-id pub-id-type="pmid">29024765</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wohlrab</surname><given-names>F.</given-names></name><name><surname>Jamieson</surname><given-names>A. T.</given-names></name><name><surname>Hay</surname><given-names>J.</given-names></name><name><surname>Mengel</surname><given-names>R.</given-names></name><name><surname>Guschlbauer</surname><given-names>W.</given-names></name></person-group> (<year>1985</year>). <article-title>The effect of 2&#x02032;-fluoro-2&#x02032;-deoxycytidine on herpes virus growth</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>824</volume>, <fpage>233</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/0167-4781(85)90053-3</pub-id><?supplied-pmid 2982405?><pub-id pub-id-type="pmid">2982405</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group> (<year>2017</year>). <source>Annual Review of Diseases Prioritized Under the Research and Development Blueprint, 2017</source>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/blueprint/what/research-development/2017-Prioritization-Long-Report.pdf?ua=1">http://www.who.int/blueprint/what/research-development/2017-Prioritization-Long-Report.pdf?ua=1</ext-link> (accessed February 7, 2020).</mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J. R.</given-names></name><name><surname>Kim</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>Y. R.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><name><surname>Oh</surname><given-names>W. S.</given-names></name><name><surname>Heo</surname><given-names>S. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Application of therapeutic plasma exchange in patients having severe fever with thrombocytopenia syndrome</article-title>. <source>Korean J. Intern. Med.</source>
<volume>34</volume>, <fpage>902</fpage>&#x02013;<lpage>909</lpage>. <pub-id pub-id-type="doi">10.3904/kjim.2016.194</pub-id><?supplied-pmid 29117665?><pub-id pub-id-type="pmid">29117665</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>R.</given-names></name><name><surname>Sakabe</surname><given-names>S.</given-names></name><name><surname>Urata</surname><given-names>S.</given-names></name><name><surname>Yasuda</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Species-specific pathogenicity of severe fever with thrombocytopenia syndrome virus is determined by anti-STAT2 activity of NSs</article-title>. <source>J. Virol.</source>
<volume>93</volume>, <fpage>e02226</fpage>&#x02013;<lpage>e02218</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02226-18</pub-id><?supplied-pmid 30814285?><pub-id pub-id-type="pmid">30814285</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X. J.</given-names></name><name><surname>Liang</surname><given-names>M. F.</given-names></name><name><surname>Zhang</surname><given-names>S. Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J. D.</given-names></name><name><surname>Sun</surname><given-names>Y. L.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Fever with thrombocytopenia associated with a novel bunyavirus in China</article-title>. <source>N. Engl. J. Med.</source>
<volume>364</volume>, <fpage>1523</fpage>&#x02013;<lpage>1532</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1010095</pub-id><?supplied-pmid 21410387?><pub-id pub-id-type="pmid">21410387</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>J. F. W.</given-names></name><name><surname>Ye</surname><given-names>Z. W.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Tsang</surname><given-names>T. G. W.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus</article-title>. <source>Viruses</source>
<volume>11</volume>:<fpage>E385</fpage>. <pub-id pub-id-type="doi">10.3390/v11040385</pub-id><?supplied-pmid 31027241?><pub-id pub-id-type="pmid">31027241</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Yin</surname><given-names>F.</given-names></name><name><surname>Moming</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>First case of laboratory-confirmed severe fever with thrombocytopenia syndrome disease revealed the risk of SFTSV infection in Xinjiang, China</article-title>. <source>Emerg. Microbes Infect.</source>
<volume>8</volume>, <fpage>1122</fpage>&#x02013;<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2019.1645573</pub-id><?supplied-pmid 31347462?><pub-id pub-id-type="pmid">31347462</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zivcec</surname><given-names>M.</given-names></name><name><surname>Safronetz</surname><given-names>D.</given-names></name><name><surname>Feldmann</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Animal models of tick-borne hemorrhagic fever viruses</article-title>. <source>Pathogens</source>
<volume>2</volume>, <fpage>402</fpage>&#x02013;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.3390/pathogens2020402</pub-id><?supplied-pmid 25437041?><pub-id pub-id-type="pmid">25437041</pub-id></mixed-citation></ref></ref-list></back></article>